Background: uPA,itsreceptoruPAR,andinhibitorsPAI-1andPAI-2playkeyroles inmembraneremodeling/invasionandinpredictingresponsetochemotherapy.We identified novel relationships of these biomarkers with ER/PR that indicate clinical utility for assessing breast carcinoma outcomes.
| INTRODUC TI ON

| Conventional biomarkers used in the management of breast cancer
Standard of care for management of breast cancer includes assessments of levels of ER, PR, and HER2 protein in the tissue biopsies. [1] [2] [3] For instance, patients with breast cancers exhibiting a biomarker subtypeofER+/PR+/HER2−typicallyhaveabetterprognosisthan thosewithtriple-negativebreastcancer.Patientswithabiomarker subtypeofER+/PR+/HER2+arecandidatesforhormonaltreatments (eg, tamoxifen, letrozole) as well as treatment with herceptin or otherhumanizedantibody-basedtherapies.However,patientswith triple-negativebreastcancershavepoorsurvivalandfewtreatment options other than chemotherapy, radiation, and surgical excision of cancers. 2, [4] [5] [6] [7] Clinically relevant cutoff values for assays, which quantified biomarkers, were established previously for each receptor that indicatedpotentialforresponsetodrugtherapyregimens(eg,tamoxifen,herceptin).Withinthepastthreedecades,theprincipalassays for the three analytes have been semi-quantitative, immunohistochemical-basedprocedures.Duetothelackofassaystandardization and related problems, the College of American Pathologists (CAP) andtheSocietyforClinicalOncology(ASCO)establishedguidelines for improving uniformity of measurements and reporting of IHC results. 2, 7, 8 Although conventional biomarkers (eg, ER, PR, and HER2 proteins)havedemonstratedutilityinmanagementprotocolsofbreast cancer, improvements in personalized treatment plans are at the forefront of cancer research. Genomic screens (eg, gene expressionprofiles)havebeendeveloped,whichassessexpressionlevels for genes whose actions and protein products are associated with breastcancerbehavior.Forinstance,anFDA-approvedmicroarray testknownasMammaPrint™usesexpressionof70genestoassess risk of breast cancer development and risk of recurrence [9] [10] [11] (website:https ://www.agend ia.com/our-tests/ mamma print/ ).
| Review of plasminogen activator system and its role in cancer growth
Aubiquitousnetworkknownastheurokinaseplasminogenactivator(uPA)systemisaproteolyticenzymesystemconsistingoffour gene members, which collectively remodel tissue basement membranes. 12, 13 ThesystemconsistsofuPA,whichisaserineprotease, itsrespectiveuPAreceptor(uPAR),whichisassociatedwiththeextracellular components of a target cell, and two inhibitors of uPA associationwithuPAR(PAI-1andPAI-2).Oneoftheprincipalfunctions of the uPA system is to convert plasminogen to plasmin to aid in the dissolution and breakdown of fibrin at clot sites in blood vessels.Inadditiontothedissolutionofclots,theuPAsystemalso has reported roles in a range of biochemical processes such as control of inflammation, angiogenesis, embryogenesis, wound healing, and cellular apoptosis. 14 Fromaclinicalstandpoint,theuPAsystem is widely documented in processes of tumor migration, angiogenesis, 15, 16 modulation of tumor microenvironments, and metastasis in a number of cancers such as lung, 17 breast, 6 ovarian, 18, 19 endometrial, 19 and pancreatic. 20 However, it is critical to consider that reportsoftheefficacyofuPAsystemmembersasprognosticmarkers in other cancers (ie, other than in breast carcinomas) remain contradictory. 21 
| Clinical application of the uPA system
The uPA system has been studied regarding cancer outcomes for nearly three decades, with one of the first suggestions for use as a prognostic marker by Duffy (cf. 12 ). Following the original report of Duffy 22 multiple studies 21, 23, 24 demonstrated use of uPA/PAI-1 expression levels as predictors of cancer outcomes in node-negativebreastcancer.Attheturnofthemillennium,largeinvestigations confirmedtheuseofquantifieduPAandPAI-1frombreastcancer patients as a measure for assessment of treatment response, progression, and outcome. [25] [26] [27] Furthermore, breast cancers exhibiting high uPA/PAI-1 levels are associated with patients with poor prognosis, yet are most responsive to adjuvant chemotherapy. 24, 28 Additionally,patientshavinghighuPA/PAI-1levelsinnode-negative 
| MATERIAL S AND ME THODS
| Remark
Summaries of patient and specimen characteristics are displayed by REMARKtables 30 forthetwodistinctpopulationsanalyzedinthis study. The first patient population summary provided in Table 1 rep-resentsthosepatientswhosetissuebiopsymeasurementsofuPA, uPAR, and PAI-1 were used in the investigations outlined in the Results section. Protein biomarker measurements were performed by earlier investigators in the laboratory according to the protocols describedfordeterminationofuPAsystemmembers. 18, 19, 31 Asummaryofpatientcharacteristicsandtissue-basedmeasurementsfor the population used in the microarray studies is given in Table 2 .
Patients were treated with standard of care of time of tissue biopsy collection, and tissue measurements were performed according to the protocols presented earlier. 3, 31, 32 
| Determination of plasminogen activator system biomarkers
ELISA analyses previously quantified uPA, uPAR, and PAI-1 levels onextractsoffreshlycollectedandfrozentissuebiopsies,storedat −86°C, using IMUBIND™ kits (formerly American Diagnostica Inc;
currently BioPacific Diagnostics, Inc) applying cutoff values previously reported. 23 Cutoff values of 3.0, 2.9, and 2.2 ng/mg protein were utilized for protein measurements of biomarkers uPA, uPAR, andPAI-1,respectively.BiomarkercutoffvaluesforuPAandPAI-1
were determined in accordance with clinically defined parameters, 23 whereas the cutoff value that we employed for uPAR protein was the median of 614 measurements from the patient population. Kits for assessing PAI-2 protein were unavailable at the time of these analyses.
BiochemicalanalysesofuPA,uPAR,andPAI-1wereperformed on extracts as described previously using freshly collected and fro- complexes according to the manufacturer. 31, 33 The final concentra-tionofeachanalytewasexpressedinngofuPA,uPAR,orPAI-1per mg extract protein.
| Determination of estrogen receptor and progestin receptor protein levels
Estrogen receptor and PR protein levels were determined previously using either the Abbott Laboratories enzyme immunoassay 
| Detection of HER2/neu in primary breast cancers
HER2/neu oncoprotein status was measured in primary breast carcinomas using either one of the two experimental antibody-based assays as described previously. 3 
| Assessment of gene expression in LCMprocured cells using microarray analyses
Results described in these investigations were collected previously 
| Assessment of gene expression in breast carcinoma tissue sections using qPCR analyses
Using qPCR results determined in our laboratory by other investigators, 37,39-41,47 gene expression levels for almost 100 genes, known to be associated with various cancers, were used in these studies to explorerelationshipswithmembersoftheuPAsystem.
| Univariable Cox regressions and survival analyses
Statistical computations, violin plots, and Kaplan-Meier plots were performed using R version 3.2.5. Utilizing commands from R package survival, 48 univariable Cox regressions of expression levels of each gene candidate estimated P-values of hazard ratios (HRs) to determine genes suggesting clinical significance. P-valueswereadjustedfor multiplecomparisonsusingtheBenjaminiandHochberg(BH)method with <0.30 selected as the "discovery" cutoff as applied earlier. 43, [49] [50] [51] Univariable Cox regression was performed on each gene candidate usingrelativeexpressionlevelstodiscernrelationshipswithprogressionfreesurvival(PFS)andoverallsurvival(OS).Thisallowstheuseofrelative gene expression values as a single covariate to investigate extent to which expression levels of a single gene in the cohort predicted PFS or
OSofbreastcancerpatients.Hazardratioswerederivedfromunivariable
Cox regression models and calculated for each of the candidate genes.
Summaries of Cox regression analyses, which utilized gene expression fromLCM-procuredbreastcarcinomacells,areprovidedinTables3and4.
| RE SULTS
| Interrelationships of biomarker protein status of the primary breast carcinoma as a function of patient age
Scatter plots were constructed in order to ascertain the relationship between patient age and quantified biomarker protein in the primary AnadjustedP-valueof<0.30wasemployedasthediscoverycutoff
for significance as described previously. 43 Results of analyses are displayed in which either ER or PR protein was measured either by radio-ligand binding or by EIA ( Figure 2 ). for either ER or PR subtypes from breast carcinomas. Median of log relative expression is indicated by a white circle, and the interquartile range is denoted with a black bar.
WheneitherERorPRlevelsweremeasuredbyradio
| Assessment of biomarker protein status as a function of HER2 protein status of the primary breast carcinoma
To assess the relationship between HER2 protein status of a primary breastcarcinomaanduPAsystembiomarker,violinplotswerecon-
cutoff value for significance. Our analyses indicated that HER2 status of the primary breast cancer was not related to protein content of ei-theruPA,uPAR,orPAI-1.
| Analysis of biomarker gene expression of the uPA pathway members as a function of ER or PR protein status of the primary breast carcinoma
Since ER is used routinely as a biomarker for prediction of breast cancer recurrence and therapy selection such as tamoxifen administration, 2 relative expression of either uPA, uPAR, PAI-1, or PAI-2 genes was examined through construction of violin plots according toER+orER−statusoftheprimarylesion(Figure4).AnadjustedPvalue of <0.30 was employed as a discovery cutoff for significance. 43 Note that relative gene expression was estimated using LCM-procured breast carcinoma cells as described in Section 2.1. These analyses revealed that expression of the uPA gene was significantly elevated in ER− cells compared to ER+ cells ( Figure 4A ). Analyses also indicated that expression of either uPAR or PAI-2 genes was sig-nificantlyelevatedinER−breastcancercellscomparedtoER+cells at an adjusted P-valueof<0.001 (Figure4B,4) .ExpressionofPAI-1 gene was not significantly expressed in regard to ER status of the primary lesion.
In addition, PR status of the primary lesion was evaluated in relation to expression of each candidate gene in LCM-procured cells.
Therefore, violin plots of PR+ and PR− lesions were constructed in relationtorelativegeneexpressionofeachgeneofinterest(Figure4).
AnalysesindicatedthatexpressionofuPA and its respective receptor, 
| Interrelationships of relative gene expression of uPA, uPAR, PAI-1, and PAI-2 as a function of HER2 protein status of the primary breast carcinoma
The HER2/neu protein status of a primary breast cancer is considered with ER and PR as a biomarker for prediction of breast cancer outcome and selection of treatment regimen. indicated that HER2 status of the primary breast cancer was not significantlyrelatedtoexpressionofanyofthefourcandidategenesanalyzed.
| Biomarker gene expression of the LCMprocured carcinoma cells as a function of menopausal status of the patient
Since the menopausal status of breast cancer patients is a clinically useful management parameter, violin plots were created to examine 
| Interrelationships of biomarker status of the primary breast carcinoma with expression of candidate genes known to be associated with cancer
From our previous studies of gene expression in primary breast carcinomas, 10, 11, 34, 39 almost 100 genes of interest have been identified whose expression we have been identified using expression levels validated by qPCR using intact tissue sections from fresh frozen biopsies. Relationships between expression of candidate cancer-relatedgenesandproteinbiomarkercontentwereanalyzed through construction of violin plots (Figure 10 ). Relative gene expression estimated by qPCR, an adjusted P-valueof<0.30employed
for significance, and biomarker cutoff values described previously were employed in these analyses. It was observed that MSX1 expression was significantly elevated in uPA+cells(Figure9A),whereas expression of RERG was elevated in uPA− carcinomas ( Figure 9B ). None of the genes examined indicated their relative expression was associated with that of either uPA, uPAR, or PAI-1 genes when a Pvalue of <0.05 was employed for significance.
| Univariable Cox regression analyses of relative gene expression according to ER and PR status of LCM-procured breast carcinoma cells
To determine the relationship between expression of each gene from microarray of the uPA system and steroid receptor status, Additionally, Gelder et al 62 analyzed PAI-2 level of cytosols pre-paredfromER+primarybreastcancersanddiscoveredasignificant relationship between high PAI-2 level and length of response to tamoxifen (ie, first-line therapy for recurrent breast cancer). Thus, our findings establishing the relationship between uPAR, PAI-1, and PAI-2 genes with clinical outcomes of patients with breast cancers exhibiting various ER status support the concept that estrogen levels are involved in regulation of these biomarkers. Current guidelines for management of primary breast carcinomas instructclinicianstoutilizeanalysesofER,PR,andHER2proteinlevels collectively to assess risk of recurrence and therapy selection. 7, 52 The results of these investigations strongly suggest that combinations of results from ER or PR protein content with measurements of eitheruPA,uPAR,orPAI-1proteinlevelsofaprimarybreastcancer biopsy provide improved assessment of a patient's clinical outcome.
| D ISCUSS I ON
Furthermore, analyses of expression of genes for the uPA, uPAR, PAI-1, and PAI-2 as well as those for ESR1(geneexpressingERmRNA and protein) and PGR (gene for expressing PR mRNA and protein)
using LCM-procured breast carcinoma cells indicated relationships betweenthesebiomarkersanddisease-freeprogressionandOSof breast cancer patients.
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